NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$154.63

-0.71 (-0.46%)

(As of 01/26/2023 12:00 AM ET)

Add

Compare

Today's Range: $152.35
▼
$156.00
50-Day Range: $147.18
▼
$160.47
52-Week Range: $125.36
▼
$169.98

Volume: 470,737 shs
Average Volume: 475,304 shs
Market Capitalization: $9.74 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $202.55

Institutional Ownership

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 31.0% Upside
$202.55 Price Target
Short Interest: Healthy
4.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.71
Based on 12 Articles This Week
Insider Trading: Selling Shares
$2.82 M Sold Last Quarter
Proj. Earnings Growth: 6.13%
From $15.18 to $16.11 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

186th out of 1,048 stocks

Pharmaceutical Preparations Industry

85th out of 513 stocks

3.5

Analyst's Opinion

Consensus Rating
Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $202.55, Jazz Pharmaceuticals has a forecasted upside of 31.0% from its current price of $154.63.
Amount of Analyst Coverage
Jazz Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.18% of the outstanding shares of Jazz Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Jazz Pharmaceuticals has recently decreased by 2.59%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Jazz Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Jazz Pharmaceuticals does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Jazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.
Environmental Sustainability
The Environmental Impact score for Jazz Pharmaceuticals is -1.96.

2.1

News and Social Media Coverage

News Sentiment
Jazz Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Jazz Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 7 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,817,148.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.
Percentage Held by Institutions
89.79% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Jazz Pharmaceuticals are expected to grow by 6.13% in the coming year, from $15.18 to $16.11 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jazz Pharmaceuticals is -515.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jazz Pharmaceuticals is -515.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Jazz Pharmaceuticals has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Jazz Pharmaceuticals has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

January 26, 2023 | finance.yahoo.com

FDA says it will not regulate CBD and calls on Congress to act

January 25, 2023 | finance.yahoo.com

Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?

January 27, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 23, 2023 | marketwatch.com

Sulfanilamide Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players Information

January 23, 2023 | marketwatch.com

Nonnarcotic Analgesics Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029

January 23, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor

January 19, 2023 | msn.com

Jazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidate

January 19, 2023 | finance.yahoo.com

Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 19, 2023 | finance.yahoo.com

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer

January 19, 2023 | finance.yahoo.com

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

January 18, 2023 | thestreet.com

Jazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings Miss

January 16, 2023 | marketwatch.com

Clozapine Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook Report

January 14, 2023 | marketwatch.com

Lewy Body Dementia Treatment Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028

January 13, 2023 | benzinga.com

Psychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViews

January 12, 2023 | marketwatch.com

Cytokine Storm Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028

January 11, 2023 | finance.yahoo.com

2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher

January 6, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)

January 6, 2023 | benzinga.com

Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?

January 3, 2023 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 | finance.yahoo.com

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022 | msn.com

Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data

December 21, 2022 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

December 20, 2022 | finance.yahoo.com

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

December 16, 2022 | marketwatch.com

Erwinase Market: Research Report on Some Key Drivers of Market Growth.

December 15, 2022 | finance.yahoo.com

Japan unit of Britain's Jazz Pharma starts phase III trial of cannabis drug

December 9, 2022 | cnbc.com

Here are Friday's biggest analyst calls: Apple, Tesla, McDonald's, Netflix, Carvana, Microsoft & more

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings: 11/09/2022
Today: 1/26/2023
Next Earnings (Estimated): 3/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:JAZZ
CUSIP: G5087110
CIK: 1232524
Web: www.jazzpharma.com
Phone: (531) 634-7800
Fax: 353-1634-7850
Employees: 3,200
Year Founded: 2003

Price Target and Rating

Average Stock Price Forecast: $202.55
High Stock Price Forecast: $225.00
Low Stock Price Forecast: $187.00
Forecasted Upside/Downside: +31.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 10.19
P/E Growth: 0.88
Net Income: $-329,670,000.00
Net Margins: -0.52%
Pretax Margin: -2.17%
Return on Equity: 30.71%
Return on Assets: 9.10%

Debt

Debt-to-Equity Ratio: 2.07
Current Ratio: 3.16
Quick Ratio: 2.27

Sales & Book Value

Annual Sales: $3.09 billion
Price / Sales: 3.15
Cash Flow: $23.18 per share
Price / Cash Flow: 6.67
Book Value: $64.51 per share
Price / Book: 2.40

Miscellaneous

Outstanding Shares: 62,966,000
Free Float: 60,195,000
Market Cap: $9.74 billion
Optionable: Optionable
Beta: 0.74

Social Links

Key Executives

Mr. Bruce C. Cozadd (Age 59)
Co-Founder, Chairman & CEO
Comp: $2.27M

Mr. Daniel N. Swisher Jr. (Age 60)
Pres & COO
Comp: $1.27M

Ms. Renee D. Gala (Age 51)
Exec. VP & CFO
Comp: $1.03M

Dr. Robert Iannone M.D. (Age 56)
Exec. VP and Global Head of R&D
Comp: $983.25k

Ms. Patricia Carr (Age 52)
Sr. VP & Chief Accounting Officer

Dr. Finbar Larkin Ph.D. (Age 65)
Sr. VP of Technical Operations

Ms. Andrea N. Flynn Ph.D.
VP & Head of Investor Relations

Ms. Neena M. Patil J.D. (Age 48)
Exec. VP & Chief Legal Officer

Dr. George Christopher Eliades Ph.D. (Age 52)
Sr. VP of Corp. Devel. & Chief Transformation Officer

Ms. Heidi Manna (Age 51)
Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.
What is Jazz Pharmaceuticals' stock price forecast for 2023?: 10 equities research analysts have issued 12-month price objectives for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they predict the company's share price to reach $202.55 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.
How have JAZZ shares performed in 2023?: Jazz Pharmaceuticals' stock was trading at $159.31 on January 1st, 2023. Since then, JAZZ shares have decreased by 2.9% and is now trading at $154.63.
View the best growth stocks for 2023 here.
When is Jazz Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast.
How were Jazz Pharmaceuticals' earnings last quarter?: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 earnings per share for the quarter, beating analysts' consensus estimates of $4.35 by $0.18. The specialty pharmaceutical company earned $940.65 million during the quarter, compared to the consensus estimate of $939.88 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 30.71% and a negative net margin of 0.52%.
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?: Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of $17.20-$17.85 for the period, compared to the consensus estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion.
What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?: 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).
What is Jazz Pharmaceuticals' stock symbol?: Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
Who are Jazz Pharmaceuticals' major shareholders?: Jazz Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.40%), Allspring Global Investments Holdings LLC (0.20%), Nepsis Inc. (0.13%), Calamos Wealth Management LLC (0.08%), Calamos Advisors LLC (0.07%) and Comerica Bank (0.07%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends.
How do I buy shares of Jazz Pharmaceuticals?: Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Jazz Pharmaceuticals' stock price today?: One share of JAZZ stock can currently be purchased for approximately $154.63.
How much money does Jazz Pharmaceuticals make?: Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.74 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.
How many employees does Jazz Pharmaceuticals have?: The company employs 3,200 workers across the globe.
Does Jazz Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?: Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

Jazz Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

JAZZ Stock News Headlines

JAZZ Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

JAZZ Stock - Frequently Asked Questions

Overall MarketRank^™